Predicting the Probability of Deferred Radical Treatment for Localised Prostate Cancer Managed by Active Surveillance

European Urology

Volumn 54, Issue 6, 2008, Pages 1297-1305

  van As, Nicholas J ^a   Norman, Andrew R ^b   Thomas, Karen ^b   Khoo, Vincent S ^a   Thompson, Alan ^b   Huddart, Robert A ^a   Horwich, Alan ^a   Dearnaley, David P ^a   Parker, Christopher C ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Active surveillance; Prognostic factors; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CLINICAL PROTOCOL; COMORBIDITY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; TREATMENT PLANNING;

ADENOCARCINOMA; AGED; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 55549120969     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.02.039     Document Type: Article

References (30)

1. Bill-Axelsen A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984
2. Albertsen P.C., Hanley J.A., Gleason D.F., and Barry M.J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280 (1998) 975-980
3. Roemeling S., Roobol M.J., Postma R., et al. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 50 (2006) 475-482
4. D'Amico A.V., Whittington R., Malkovicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
5. Zelefsky M.J., Lyass O., Fuks Z., et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 16 (1998) 3380-3385
6. Chism D.B., Hanlon A.L., Horwitz E.M., Feigenberg S.J., and Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 380-385
7. Warlick C., Trock B.J., Landis P., Epstein J.I., and Carter H.B. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98 (2006) 355-357
8. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
9. Choo R., De Boer G., Klotz L., et al. PSA Doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 50 (2001) 615-620
10. Choo R., Klotz L., Danjoux C., et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167 (2002) 1664-1669
11. Terris M.K., and Stamey T.A. Determination of prostate volume by transrectal ultrasound. J Urol 145 (1991) 984-987
12. De Vries S.H., Postma R., Raaijmakers R., et al. Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. Eur Urol 51 (2007) 366-374
13. Carter H.B., Walsh P.C., Landis P., and Epstein J.I. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 167 (2002) 1231-1234
14. Klotz L. Active surveillance for prostate cancer: for whom?. J Clin Oncol 23 (2005) 8165-8169
15. Khan M.A., Carter H.B., Epstein J.I., et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?. J Urol 170 (2003) 2274-2278
16. Meng M.V., Elkin E.P., Harlan S.R., Mehta S.S., Lubeck D.P., and Carroll P.R. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol 170 (2003) 2279-2283
17. Roddam A.W., Duffy Mj, Hamdy F.C., et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 48 (2005) 386-399 discussion 398-9
18. Nam R.K., Toi A., Klotz L., et al. Assessing individual risk for prostate cancer. J Clin Oncol 25 (2007) 3582-3588
19. Raaijmakers R., De Vries S.H., Blijenberg B.G., et al. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Eur Urol 52 (2007) 1358-1364
20. Steuber T., Vickers A.J., Serio A.M., et al. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 53 (2007) 233-240
21. Roemeling S., Roobol M.J., De Vries S.H., et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 51 (2007) 1244-1251 discussion 1251
22. Khatami A., Aus G., Damber J.E., Lilja H., Lodding P., and Hogosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 120 (2007) 170-174
23. Hardie C., Parker C., Norman A., et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 95 (2005) 956-960
24. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
25. Carter H.B., Ferrucci L., Kettermann A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521-1527
26. D'Amico A.V., Renshaw A.A., Sussman B., and Chen M.H. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
27. Fall K., Garmo H., Andren O., et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 99 (2007) 526-532
28. Cuzick J., Fisher G., Kattan M.W., et al. Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95 (2006) 1186-1194
29. Venkitaraman R., Norman A., Woode-Amissah R., et al. Predictors of histological disease progression in untreated, localized prostate cancer. J Urol 178 (2007) 833-837
30. Venkitaraman R., Norman A., Woode-Amissah R., et al. Prostate-specific antigen velocity in untreated* localized prostate cancer. BJU Int 101 (2008) 161-164